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Abstract
BACKGROUND—Significant cardiac neural and electrophysiologic remodeling occurs with
hypercholesterolemia (HC). Whether simvastatin can reverse HC-induced remodeling is unclear.
OBJECTIVE—The purpose of this study was to determine the mechanisms underlying the
antiarrhythmic effects of statins.
METHODS—Rabbits (N = 38) were fed HC chow (HC), standard chow (Control), HC chow
followed by standard chow (Withdrawal), or HC chow and simvastatin (Statin) for 8 weeks. The
hearts then were Langendorff-perfused for electrophysiologic studies. Nerves were identified by
immunostaining of growth-associated protein-43 (GAP43) and tyrosine hydroxylase (TH). Action
potential duration (APD) restitution in normal hearts with (N = 5) and without (N = 5) simvastatin
therapy also was studied.
RESULTS—Serum cholesterol levels (mg/dL) were 1,855 ± 533 in HC, 50 ± 21 in Control, 570 ±
115 in Withdrawal, and 873 ± 112 in Statin groups (P <.001). Compared with HC (16,700 ± 5,342;
12,200 ± 3,878 µm2/mm2), the Statin group had significantly reduced GAP43-positive (10,289 ±
3,393 µm2/mm2, P = .03) and TH-positive (7,685 ± 2,959 µm2/mm2, P = .04) nerve density,
respectively. APD was longer in HC rabbits than in controls (192 ± 20 ms vs 174 ± 17 ms; P <.03).
Withdrawal and Statin groups had less APD prolongation than HC group. Statin group has less
repolarization heterogeneity than HC group (P <.01). Statin therapy flattened the slope of APD
restitution in normal hearts. Ventricular fibrillation was either induced or occurred spontaneously in
79% of hearts in HC, 20% in Control, and 66% in Withdrawal groups. However, there was no VF
in hearts of Statin group (P <.001).
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CONCLUSION—Simvastatin significantly reduced vulnerability to ventricular fibrillation via the
mechanism of reduction of HC-induced neural and electrophysiologic remodeling.
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Introduction
Hypercholesterolemia (HC) in rabbits produces significant cardiac proarrhythmic neural and
electrical remodeling.1–4 Dyslipidemia increases the incidence of ventricular tachycardia/
ventricular fibrillation (VT/VF) after acute myocardial infarction.5 Lipid-lowering therapy
using statins reduces VT/VF in patients with an implantable cardioverter-defibrillator (ICD).
6,7 Furthermore, statin use was associated with a significant reduction in sudden cardiac death
in addition to preventing VT/VF.7,8 Many other studies also found that statin use improved
surrogate markers of arrhythmic risk in a population at certain risk for arrhythmic events.9,10
These findings support the notion that statin use is antiarrhythmic. However, the mechanisms
by which statins are antiarrhythmic remain unclear. Our previous study indicated that HC in
rabbits can induce significant proarrhythmic neural and electrophysiologic remodeling.1
Therefore, we hypothesize that statin is antiarrhythmic because it reverses the proarrhythmic
remodeling induced by HC. The purpose of the present study was to test this hypothesis.
Methods
All animal study protocols were approved by the Animal Care and Use Committee and
conformed to the guidelines of the American Heart Association. Three-month-old female New
Zealand white rabbits were used for the study. Total serum cholesterol and triglyceride levels
were determined before the animals were sacrificed.
Animals and diets
The rabbits were fed according to the following dietary protocols:
• Control group: Ten rabbits were fed with standard chow (Purina 5321) for 8 weeks.
• HC group: Fifteen rabbits were fed high fat and cholesterol chow (Purina 5321 + 0.5%
cholesterol + 5% coconut oil) for 8 weeks.
• Withdrawal group: Six rabbits were fed with high fat and cholesterol chow for 6
weeks, followed by standard chow for 2 weeks.
• Statin group: Seven rabbits were fed with high fat and cholesterol chow and
simvastatin 20 mg/day for 8 weeks.
To demonstrate the effects of statin on action potential duration (APD) restitution in rabbits
without HC, two additional groups were included:
• Control group: Five rabbits fed with standard chow for 8 weeks.
• Statin group: Five rabbits fed with standard chow and simvastatin 20 mg/day for 8
weeks.
Immunocytochemical study
Ventricular tissues of rabbit hearts were fixed in 4% formalin for 1 hour, followed by 70%
alcohol, and cross-sectioned from apex to base. Three sections of each heart were used for
immunocytochemical studies. Details of the staining techniques have been reported elsewhere.
1,11 In brief, anti–growth-associated protein-43 (GAP43) and anti-tyrosine hydroxylase (TH)
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antibodies (monoclonal mouse anti-GAP43 and anti-TH, respectively, 1:50 dilution; Chemicon
International, Inc., Billerica, MA, USA) were used for immunocytochemical staining. GAP43
is a marker for nerve sprouting.12 TH is a marker of sympathetic nerves.13 Nerve density was
determined by computerized morphometry (Image-Pro Plus 4.0, Media Cybernetics, Inc.,
Bethesda, MD, USA).1 The nerve density was the nerve area divided by the total area examined
(µm2/mm2). Each slide was examined under a microscope with 20× objectives. For data
analyses, the slides were divided into four quadrants. and one microscopic field with the highest
nerve density from each quadrant was selected for nerve counting. Because three sections were
taken for each heart, a total of 12 microscopic fields were counted. The average nerve density
of all selected fields was used to represent the nerve density of that heart.
Isolated rabbit heart preparation and electrophysiologic study
The hearts were quickly removed during anesthesia and Langendorff-perfused with 37°C
Tyrode’s solution of the following composition (in mM): 125 NaCl, 4.5 KCl, 0.25 MgCl2, 24
NaHCO3, 1.8 NaH2PO4, 1.8 CaCl2, and 5.5 glucose, equilibrated with 95% O2 and 5% CO2,
pH 7.4. Coronary perfusion pressure was regulated between 80 and 95 mmHg. Pseudo-
electrocardiogram (ECG) registered with a widely spaced bipole was used to monitor heart
rhythm. Electrical stimuli of 2-ms duration and two to three times the diastolic threshold were
delivered through a catheter in the right ventricle. Ventricular vulnerability was tested with
single and double extrastimuli given after eight S1 at a pacing cycle length (PCL) of 400 ms.
Premature coupling intervals initially were paced at 380 ms, then shortened successively until
the effective refractory period was reached or fibrillation was induced. After baseline studies,
0.1 µM isoproterenol and repeated programmed stimulations were given to induce arrhythmia.
Optical mapping studies were performed using a setup similar to that reported in a previous
study.14 The tissues were stained with 0.5 µM di-4-ANEPPS (Molecular Probes, Eugene, OR,
USA). An electromechanical uncoupler (cytochalasin D 5 µM; Sigma Inc., St. Louis, MO,
USA) was used to inhibit motion. Laser light of 532-nm wavelength (Verdi, Coherent Inc.,
Santa Clara, CA, USA) illuminated the tissues, and epifluorescence was collected through a
long-pass filter with a cutoff wavelength of 600 nm (R60, Nikon, Melville, NY, USA) and a
high-speed charge-coupled device (CCD) camera (420 frames/s, model CA D1-0128T, Dalsa
Inc., Waterloo, Ontario, Canada). APD was measured at PCL of 400, 300, and 200 ms. One
hundred points over the ventricular anterior wall were selected for APD analysis. A computer
algorithm automatically determined APD80. The standard deviation (SD) and the difference
(between the longest and shortest APD80) of APD80 were used to represent APD dispersion.
APD restitution was determined by a dynamic pacing protocol.15 The ventricles initially were
paced at a constant cycle length of 400 ms. PCL was shortened successively in steps of 20 ms
for PCL >200 ms and in steps of 10 ms for PCL <200 ms until PCL = 100 ms or loss of 1:1
ventricular capture. Restitution curves were constructed from APD80 and the preceding
diastolic intervals at nine evenly spaced sites on the left ventricular anterior wall using data
obtained during pacing. The maximal slope of APD restitution curve was determined after
curve fitting by first-order exponential fitting with Origin software (Micro-Cal, Northampton,
MA, USA). Conduction velocity (CV) along three different directions from the S1 pacing site
at PCL of 300 ms was measured. The mean of the three values was used as the CV (cm/s) for
that heart.4,14
Statistical analysis
Values are expressed as mean ± SD. Analysis of variance for repeated measurements with
Newman-Keuls test was used to determinate the significance of between-group comparisons.
P ≤.05 was considered significant.
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Results
Table 1 summarizes the serum cholesterol and triglyceride concentrations in the first four
groups. Serum cholesterol levels were significantly higher in the HC group than in the Control
group. Statin treatment resulted in a 53% reduction in serum cholesterol levels compared with
the HC group (P <.001). The cholesterol levels in Statin group were significantly higher than
in the Withdrawal group. There were no significant differences of serum triglyceride levels
among the four groups.
Nerve sprouting and sympathetic hyperinnervation
As we previously reported,1 significant neural remodeling occurred in HC rabbits. Figure 1A
shows examples of GAP43 immunocytochemical staining. Nerve sprouting was much more
abundant in HC group than in control group. Sprouting nerves were fewer in Withdrawal and
Statin groups than in HC group. As shown in Figure 1B, GAP43(+) nerve density in HC (16,700
± 5,342 µm2/mm2), Withdrawal (12,767 ± 832 µm2/mm2), and Statin (10,289 ± 3,393 µm2/
mm2) groups all were significantly higher in than Control group (4,925 ± 1,452 µm2/mm2;
P <.05). Compared with HC group, Statin group had a significant reduction in GAP43(+) nerve
density (P = .03). Figure 2A shows examples of TH immunocytochemical staining.
Sympathetic innervation was much more abundant in HC group than in Control group. TH(+)
nerves were also fewer in Withdrawal and Statin groups than in HC group. As shown in Figure
2B, TH(+) nerve density in HC (12,200 ± 3,878 µm2/mm2), Withdrawal (7,400 ± 872 µm2/
mm2), and Statin (7,685 ± 2,959 µm2/mm2) groups all were significantly higher than in Control
group (3,250 ± 1,420 µm2/mm2; P <.05). Compared with HC group, Statin group had a
significant reduction in TH(+) nerve density (P <.05). For all stained samples, there was a
significant correlation between serum cholesterol level and nerve density of GAP43(+) nerves
(r = 0.61, P = .005) and between serum cholesterol level and nerve density of TH(+) nerves (r
= 0.68, P = .002).
APD, APD dispersion, and APD restitution characteristics
Figure 3A shows typical examples of action potentials in rabbits of the four groups at PCL of
400 ms at baseline. The HC group showed significant APD prolongation and increased APD
dispersion after 8 weeks of feeding. APD was less prolonged in Withdrawal and Statin groups.
However, there still was a large APD heterogeneity in Withdrawal group. The alterations in
APD80 and APD80 dispersion are summarized in Figure 3B. Mean APD80 of the anterior wall
at PCL of 400 ms was significantly longer in HC group than Statin group (APD80: 192 ± 20
ms vs 174 ± 17 ms; P <.03). There was a 34% and 59% reduction in mean APD prolongation
in Withdrawal and Statin groups, respectively, compared with HC group at PCL of 400ms.
The longest APD80 of the anterior wall in the HC group was significantly increased compared
with Statin group at all three PCLs. There was a 42% and 85% reduction in longest APD
prolongation in Withdrawal and Statin groups, respectively, compared with HC group at PCL
of 400 ms. The spatial heterogeneity of APD, represented as either the SD of APD80 at 100
points or the difference between the longest and shortest APD80 over the anterior wall, also
was significantly greater in HC group compared with Control group (PCL = 400 ms: SD: 8.3
± 3.1 ms vs 5.5 ± 2.0 ms, P <.05; difference: 42.5 ± 18.2 ms vs 25.1 ± 7.3 ms, P <.01). The
spatial heterogeneity of APD was significantly decreased in Statin group (SD: 4.4 ± 1.1 ms;
difference: 19.2 ± 5.9 ms) than in HC group (P <.01). Note that the heterogeneity of Statin
group at each PCL was less than in the Control group; however, the difference was not
statistically significant.
Figure 4 A shows typical examples of APD restitution curves in the four groups. Figure 4B
summarizes the alterations in the maximum slope of APD restitution curves of all four groups.
Both the mean and highest maximum slope of APD restitution (i.e., highest value of the entire
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mapped region) were significantly decreased in Statin group than in Control group (mean: 1.24
± 0.21 vs 1.57 ± 0.24; P <.05; highest: 1.44 ± 0.23 vs 2.07 ± 0.33; P <.01). In normal hearts,
8-week simvastatin treatment significantly flattened the mean and highest maximum slope of
APD restitution (statin vs control; mean: 0.97 ± 0. 1 vs 1.32 ± 0.12; P = .001; highest: 1.23 ±
0.09 vs 1.67 ± 0.11; P <.001). Figure 5 summarizes the effects of simvastatin on APD restitution
in normal rabbits.
Conduction velocity
CV was significantly less in HC group (56.4 ± 6.2 cm/s) than Control group (63 ± 6.5 cm/s,
P = 0.02). CV in Withdrawal (57.8 ± 6.6 cm/s) and Statin (61.2 ± 9 cm/s) groups were between
these values, but these differences were not statistically significant.
Ventricular vulnerability to fibrillation
Figures 6A and 6B show examples of spontaneous or induced VF in HC and Withdrawal
groups. VF was either induced or occurred spontaneously in 79% of hearts in HC, 20% in
Control, and 66% in Withdrawal groups (Figure 6C). There was no VF in the Statin group
(P <.001).
Discussion
This study shows that simvastatin significantly reduced neural and electrophysiologic
remodeling induced by HC and reduced vulnerability to VF. Because the Withdrawal group
had a lower cholesterol level than the Statin group but continued to have inducible VF, these
data suggest that the antiarrhythmic effects of simvastatin may not be attributed to cholesterol-
lowering effects alone.
Antiarrhythmic actions of statins in clinical trials
Lipid-lowering interventions have been shown to reduce coronary events and all-cause
mortality.16 It is possible that some of the beneficial effects of lipid-lowering therapy can be
attributed to the reduction of VT/VF and sudden death. In an observational study, DeSutter et
al17 reported that in patients with coronary artery disease receiving an ICD, treatment with
lipid-lowering drug therapy resulted in a substantial reduction in appropriate shocks. Mitchell
et al6 sought to evaluate the antiarrhythmic effects of lipid-lowering therapy in patients enrolled
in the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial. In patients with an ICD
for secondary prevention of sudden cardiac death, use of lipid-lowering drug therapy was
associated with a 40% reduction in the relative hazard for VT/VF recurrence. In the Multicenter
Automatic Defibrillator Implantation Trial II (MADIT-II), a primary prevention trial of sudden
cardiac death, statin use was associated with a reduction in the risk of sudden cardiac death or
VF.7 The antiarrhythmic properties of statin could also be demonstrated in patients with
nonischemic dilated cardiomyopathy in that statin use significantly reduced arrhythmic sudden
death.18 These secondary analyses of large clinical trials have provided strong supportive
evidence for the beneficial effects of statins on life-threatening ventricular arrhythmias.
Effects of statins on electrophysiologic remodeling induced by HC
Vrtovec et al10 explored the potential antiarrhythmic benefit of atorvastatin in patients with
advanced heart failure. They found that atorvastatin shortened the QTc interval and thereby
may have reduced the risk of arrhythmias. In subjects with isolated hypercholesterolemia,
simvastatin could normalize QTc dispersion and reduce ventricular premature complexes.9
These studies indicate that statins have significant effects on cardiac electrophysiologic
properties. Consistent with these clinical findings, we found that simvastatin reduced HC-
induced APD prolongation, decreased repolarization heterogeneity, and flattened APD
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restitution. Simvastatin also attenuated the effects of HC-induced conduction slowing.4 These
findings suggest that statins achieve their antiarrhythmic drug action in part by preventing or
reversing electrophysiologic remodeling induced by HC.
Effects of statins on neural remodeling induced by HC
Our previous studies showed that HC induced significant cardiac nerve sprouting and
sympathetic hyperinnervation in both immunocytochemical studies in vitro and 123I-MIBG
imaging in vivo in HC rabbits.1,2 Furthermore, there is an excellent dose–response relationship
between serum cholesterol level and nerve density for GAP43(+) and TH(+) nerves.1 The
present study demonstrated that simvastatin use in HC rabbits reduced nerve sprouting and
sympathetic hyperinnervation induced by HC. Two-year atorvastatin treatment may increase
heart rate variability in patients with hypercholesterolemia, with or without coronary artery
diseases.19 Vrtovec et al10 also showed that atorvastatin therapy increases heart rate variability
and decreases QT variability in patients with advanced heart failure. These human studies are
compatible with a relative reduction of sympathetic tone versus parasympathetic tone after
atorvastatin treatment. Putting together these findings, we propose that preventing or reversing
neural remodeling might play a role in the antiarrhythmic drug action of statin therapy.
Lipid-lowering independent antiarrhythmic effects of statins
The results of the present study also suggest that simvastatin might have independent
antiarrhythmic effects. Withdrawal group had lower cholesterol level than Statin group but
continued to have inducible VF. In comparison, electrophysiologic and neural remodeling was
less apparent in Statin group, despite higher cholesterol levels, compared with Withdrawal
group. We also found that simvastatin therapy flattened the slope of APD restitution not only
in HC hearts but also in normal hearts. Thus, the antiarrhythmic effects of simvastatin may not
be attributable to lipid-lowering effects alone. Several plausible mechanisms might underlie
the lipid-lowering independent antiarrhythmic actions of statin. First, atorvastatin appeared to
desensitize neonatal rat cardiomyocyte to beta-adrenergic stimulation by a mechanism that
involves the G-protein cellular content and cAMP accumulation.20 Second, simvastatin has
been demonstrated to elevate the sarcoplasmic reticulum Ca2+ - ATPase and ryanodine receptor
2 in both gene and protein expression, suggesting increased sarcoplasmic reticulum Ca release
and uptake during cardiac cycle.21 Third, statins also could interact with the lipid bilayer of
the cell membrane,22 which may affect electrical stability and mitochondrial function.
Lovastatin decreased sarcolemmal Na+/K+ ATPase pump density in cardiac myocyte, leading
to increased sarcoplasmic Na+ concentration that might alter intracellular calcium dynamics
through the Na+/Ca2+ exchanger.23 Statins appear to suppress intracellular calcium
mobilization and membrane current induced by lysophosphatidylcholine in endothelial cells
by preventing Rho kinase activation.24 Simvastatin increases mitochondrial NADH content
and induced mitochondrial membrane depolarization and calcium efflux.25 Of note, these
mechanisms are independent of statin HMG-CoA reductase activity. The lipid-lowering
independent effects have also been documented by a study using pravastatin, which is water
soluble and has a different biodistribution than other statins. In that study, hydrophilic
pravastatin prevented reperfusion-induced lethal VF in normocholesterolemic rats.26
Study limitations
The electrophysiology studies were performed with Langendorff perfusion. It is possible that
electrophysiologic parameters are different when the hearts were in situ and when the rabbits
were conscious. Only one statin was statin was tested in this study. Whether the results can be
generalized to all statin drugs is unclear. Because simvastatin reduced both electrophysiologic
and neural remodeling, it is difficult to determine which of the two is primarily or solely
responsible for the increased vulnerability.
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Figure 1.
Immunohistologic studies of cardiac nerve sprouting. A: Examples of immunostaining results
with anti– growth-associated protein-43 (GAP43) antibody in the four groups. Nerves are
labeled red. B: Summary of nerve density (µm2/mm2) in the four groups. *P <.05 vs control
group; †P <.05 vs hypercholesterolemia (HC) group.
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Figure 2.
Immunohistologic studies of cardiac sympathetic nerve density. A: Examples of
immunostaining results with anti- tyrosine hydroxylase (TH) antibody in the four groups.
Nerves are labeled red. B: Summary of nerve density (µm2/mm2) in the four groups. * P <.05
vs control group; †P <.05 vs hypercholesterolemia (HC) group.
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Figure 3.
Effects of simvastatin on action potential duration (APD). A: Examples of action potentials at
pacing cycle length of 400 ms in the four groups with shortest (dotted line) and longest (solid
line) APD over anterior wall. B: Summary of mean, maximum (Max.), standard deviation
(SD), and difference of APD80 (100 points) over the anterior wall in the four groups. Scale for
both ordinate and abscissa of each graph is in milliseconds. C = Control; HC =
Hypercholesterolemia; ST = Statin; WD = Withdrawal. *P <.05 vs control group; †P <.05 vs
HC group.
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Figure 4.
Effects of simvastatin on action potential duration restitution (APDR). A: Examples of APD
restitution curves at nine different sites in the left ventricular anterior wall in the four groups.
The maximum slope of APD restitution is labeled in the lower right corner of each curve. The
ordinate in each graph is APD in milliseconds; the abscissa is diastolic interval in milliseconds.
The same scales are used in all graphs of each panel. B: Summary of the mean and highest
values of maximum slope of APD restitution in the four groups. *P <.05 and †P <.001 vs
control group.
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Figure 5.
Effects of simvastatin on action potential duration restitution (APDR) in normal rabbits. A:
Examples of APD restitution curves at nine different sites in the left ventricular anterior wall.
The maximum slope of APD restitution is labeled in the lower right corner of each curve. The
ordinate in each graph is APD; the abscissa is diastolic interval. The same scales are used in
all graphs of each panel. B: Summary of the mean and highest values of maximum slope of
APD restitution. *P = .001 and †P <.001 vs normal hearts not treated with simvastatin.
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Figure 6.
Effects of hypercholesterolemia (HC) and simvastatin on ventricular arrhythmia. A: Examples
of ventricular tachyarrhythmia induced by single and double ventricular extrastimuli in HC
and Withdrawal groups. B: Under isoproterenol infusion, ventricular tachyarrhythmia occurred
more frequently in HC and Withdrawal groups than in Control and Statin groups. C: Summary
of occurrence of ventricular fibrillation (VF) in the four groups. C = Control; ST = Statin; WD
= Withdrawal.
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Table 1
Serum lipid profiles
Cholesterol level
(mg/dL)
Triglyceride level
(mg/dL)
Control group 51 ± 26 39 ± 7
Withdrawal group 494 ± 227*†‡ 26 ± 11
Statin group 873 ± 112*† 63 ± 77
Hypercholesterolemia group 1,855 ± 533* 105 ± 94
*
P <.001 vs control group.
†
P <.001 vs hypercholesterolemia group.
‡
P <.01 vs statin group.
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